m0324
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2025 (NCT07166601)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD40 agonist
- Mucin-1INHIBITOR
MUC1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07166601 | Phase 1 | Oct 10, 2025 | Merck KGaA, Merck Serono |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 1 | 0 | 1 | 2025 |
| Merck Serono | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1